ELVN - CIK 0001672619
The table below shows Enliven Therapeutics, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $85.86M | $80.78M | $64.57M | $31.02M | $20.47M | $32.15M |
| SG&A | $33.80M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $23.78M |
| $18.95M |
| $7.77M |
| $4.29M |
| $9.54M |
| Operating income | -$119.66M | -$104.55M | -$83.53M | -$38.79M | -$24.76M | -$41.70M |
| Income tax | $0.00 | $232.00K | $0.00 | $0.00 | - | - |
| Net income | -$103.70M | -$89.00M | -$71.58M | -$37.66M | -$24.74M | -$41.36M |
| EPS (diluted) | -$1.83 | -$1.89 | -$2.01 | -$12.05 | -$10.73 | - |